<mxlb class="upplj"></mxlb>

公海555000官网

Be the most trusted biotech company

2025-11-21

Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
2025-11-17

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
2025-11-14

Serplulimab Approved in Peru, Expanding into LATAM
2025-11-12

The UK Medicines and Healthcare Products Regulatory Agency Approves BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2025-11-04

Goldman Sachs Initiates "Buy" Rating on Henlius, Sees Global Innovation Driving New Value Reassessment
2025-11-03

Henlius Presents Updated Clinical Data on PD-L1 ADC HLX43 for NSCLC at 2025 International Summit on Frontiers and Innovation in Lung Cancer
2025-11-03

Henlius Announces Updated Follow-up Results of Anti-EGFR MAb HLX07 Combined with Serplulimab in First-Line Treatment of EGFR-High Squamous NSCLC
2025-11-03

Henlius Shines at CPHI 2025: Accelerating Global Access to China’s Biopharma Innovations
2025-10-23

On Site at JSCO | Henlius Advances Treatment Innovations in High-Incidence Cancers Across Asia